Reif A
University Medical Center Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt am Main, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany. Electronic address: reif@med.uni-frankfurt.de.
ArticleKetamine
Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].
ArticleKetamine
Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report.
ArticleKetamine
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".
Article5-MeO-DMT
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
ArticleKetamine
Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.
ArticleKetamine
Efficacy and safety of esketamine on major depression, postpartum depression and perioperative depression: a systematic review and meta-analysis.
ArticleKetamine
Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.
ArticleKetamine
Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.
ArticleKetamine
Top-line Results from ESCAPE-LTE: An Open-Label Extension Study to Assess Long-term Safety of Esketamine Nasal Spray in Treatment Resistant Depression
ArticleKetamine
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial - ERRATUM.
ArticlePsilocybin
Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action.
ArticleKetamine
Effects of repeated intravenous esketamine administration on affective biases.
ArticleKetamine
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.
ArticleKetamine
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression.
ArticleKetamine
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.
ArticleKetamine
Esketamine Nasal Spray versus Quetiapine for Resistant Depression. Reply.
ArticleKetamine
Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial
ArticlePsychedelics